Participated · Equity · May 2026

Founded in 2012 and headquartered in Los Angeles, Rightsline offers a unified rights and royalties platform that spans rights management, royalty calculation, financials, and accounting. The company serves more than 300 large organizations across eight IP-intensive verticals, including media and entertainment, publishing, consumer products, life sciences, technology, gaming, music and franchising. Its platform processes more than $40 billion in royalties annually and manages over 150 million IP assets across 28 countries. Rightsline reported record growth in bookings, revenue and retention in 2025 and another record quarter in Q1 2026. The company has begun shipping AI-powered products, including an AI contract ingestion assistant and a natural-language rights and availabilities assistant, and plans to accelerate that roadmap and expand internationally following the new investment.

Participated · Seed · Apr 2025

GenrAb discovers and develops naturally occurring, fully‑human neuroprotective antibodies using proprietary immunogenetic models applied to cerebrospinal fluid from patients with active neurological disease. Its lead candidate, TGM‑010, has repeatedly demonstrated the ability to cross the blood‑brain barrier, internalize into neurons, and engage stress‑management machinery to reduce neurological disability. The company says it is building a growing pipeline of partnerable neurotherapeutic antibodies selected for antineuronal capabilities and potential to manage neuronal stress. Proceeds from the announced financing will allow GenrAb to emerge from stealth and accelerate TGM‑010 through IND enabling work toward human clinical studies in 2026. GenrAb was founded on technology exclusively licensed from UT Southwestern Medical Center and is headquartered in BioLabs at Pegasus Park in Dallas. The company has received multiple regional awards recognizing its approach to treating neurodegeneration.

Led · Series A · Jul 2019

OncoNano Medicine is a Southlake, Texas–based medical company that exploits pH as a biomarker to diagnose and treat cancer. Its product portfolio includes solid tumor therapeutics, agents for real-time image-guided surgery, and a platform of product candidates that activate and guide the body’s immune system to target cancer. The company is developing pegsitacianine, an innovative real-time imaging agent used in intraoperative surgical resection of solid tumors. It also is advancing an internal therapeutic development program, ONM-501, a novel immune-therapeutic formulated with its core delivery technology. OncoNano intends to use the funds to support Phase 3 clinical trials in the U.S. and Europe for pegsitacianine and to accelerate advancement of ONM-501. The company is led by CEO Martin Driscoll. OncoNano Medicine develops products that exploit pH as a biomarker to diagnose and treat cancer, centered on a proprietary pH-activated micelle platform. Its lead candidate, pegsitacianine, is a fluorescent nanoprobe under study as a real-time intraoperative imaging agent for solid tumor resection and is in Phase 2 trials. The company is also advancing ONM-501, a next-generation dual-activation STING agonist immuno-therapeutic, toward first-in-human studies. Proceeds from the recent financing will support initiation of pivotal Phase 3 trials of pegsitacianine in the U.S. and Europe and help accelerate ONM-501 through IND submission and Phase 1a/1b trials. OncoNano says the Series B funds combined with support from the Cancer Prevention & Research Institute of Texas will provide resources to operate for several years and advance pegsitacianine toward commercialization. The company is based in Southlake, Texas. OncoNano’s lead product, ONM-100, uses a pH-sensitive micelle platform that activates a fluorescent tag in the acidic tumor microenvironment to enable intraoperative imaging of solid tumors. ONM-100 is in Phase 2 clinical trials and has received FDA Fast Track designation. During trials the company found ONM-100 can also image and stage metastatic disease, and the company plans to expand its application to identify metastatic deposits in the peritoneum, lymph nodes and pleural surfaces. OncoNano also advances ONM-500, a candidate that leverages the same micelle technology to deliver antigens and activate innate immunity for HPV-associated cancers. The company has received multiple CPRIT awards to support development of these programs. OncoNano is based in Southlake, Texas. OncoNano Medicine is developing a platform of pH-sensitive micelles that detect diseased tissue and enable targeted imaging and therapeutic applications. Its lead product, ONM-100, is an intravenously administered intraoperative imaging agent that detects tumors and metastatic lymph nodes. The company completed a Phase 1 trial of ONM-100 that reported a 100% imaging response in patients and has an IND accepted by the FDA; ONM-100 is entering a Phase 2 clinical trial and a separate application received Fast Track designation. OncoNano is applying the same micelle platform to therapeutic candidates, including a T-cell activator that targets lymph nodes and dendritic cells, and exploring cancer vaccine applications. Proceeds from the recent financing are intended to fund the imaging clinical trials and support expansion into therapeutic programs. OncoNano Medicine develops a new class of pH-activated compounds that digitalize and exploit pH variability to detect and treat diseased tissue. Its lead program, ONM-100, is an injectable imaging agent designed to target acidic pH within tumors to help surgeons distinguish cancer from healthy tissue in real time during surgery. ONM-100 is intended to fit seamlessly with current surgical practices for intraoperative assessment, cancer staging, and post-surgery evaluation of lymph nodes and tumor margins. The company announced a $11.7 million Series A financing to support continued clinical development of the platform and to expand applications across therapeutics and imaging agents. This Series A supplements a prior $6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The platform’s technology was invented at the University of Texas Southwestern Medical Center, and the inventors remain engaged on the company’s scientific advisory board. OncoNano also appointed five established industry leaders to its board to support its clinical and commercial progress.

Participated · Equity · Apr 2019

Lucid Sight is an independent game studio and developer of Colyseus Arena, a fully managed cloud-hosted multiplayer service that handles server management, infrastructure, and scaling for games. The company acquired Colyseus, an open-source Node.js multiplayer framework, earlier this year and keeps the framework open-source while building a paid managed service. Colyseus Arena offers a free indie/dev tier, global availability across seven data centers, auto-scaling, enterprise load balancing, DDoS protection, and DevOps-as-a-service. Lucid Sight says hundreds of customers have signed up for Early Access and that customers’ games support millions of daily active users. The Colyseus open-source framework has had over 300,000 downloads since creation (about 10,000 downloads per month) and Lucid Sight reports over 5,000 projects started each month with 3,000 developers active in social channels. The company is based in Los Angeles and was founded in 2015. Lucid Sight develops blockchain-based games that emphasize digital ownership, including MLB Champions and Crypto Space Commander (CSC). The company plans to expand those titles to traditional gaming platforms — mobile, PC, and console — and expects a PC early access release of CSC on Steam in 2019. It is building Scarcity Engine, a developer tool that powers MLB Champions and CSC and is intended to bridge blockchain and traditional gaming platforms; Scarcity Engine 1.0 will launch later this year with select third-party developers. MLB Champions is an officially licensed MLB Advanced Media and MLBPA product, and CSC is described as a sandbox MMO with a real-time, player-controlled economy. Lucid Sight previously focused on an ad-supported VR game development platform but pivoted away from that business. The company has strategic partnerships to expand into Asia, including a deal with Animoca Brands. Financially, Lucid Sight has raised $11 million to date, including the new $6 million financing. Lucid Sight is an LA-based VR game studio that builds immersive titles and a VR Ad SDK to help developers monetize with in-app, immersive ads. The studio currently has three titles—Poly Runner VR, Gumi No Yume, and Space Bit Attack—available across major headsets and plans to expand to 20 free, ad-supported titles by year-end. Coinciding with its recent fundraise, Lucid Sight released a VR Ad SDK and says it will use the new capital to build out its content library, broaden presence across headsets, and showcase the ad platform. Financially, the company closed a $3.5M Series A that brings total funding to $4M. The founders, Randy Saaf and Octavio Herrera, previously built Jirbo into AdColony and later sold it to Opera, providing the team with prior ad-network and mobile experience. Early operating metrics cited include over 20% of users watching the full four-minute sponsored ad in PolyRunner VR (with an opt-out after 10 seconds) and the studio reporting its games are on a "high double-digit percentage" of Gear VR devices while Oculus said Gear VR surpassed 1 million users.

Participated · Convertible Note · Nov 2018

AsclepiX Therapeutics is a clinical-stage biopharmaceutical company in Baltimore, MD that leverages computational biology to identify potent peptide regulators of vascular homeostasis for retinal diseases. The company was founded by Johns Hopkins University School of Medicine researchers who initially licensed a portfolio of vascular homeostatic peptides and technologies. Its lead candidate, AXT107, is presented as a microparticulate suspension suitable for intraocular injection. AXT107 inhibits pro-angiogenic VEGFR2 and activates the vessel-stabilizing receptor Tie2 via interactions with integrin αvβ3 and integrin α5β1, addressing two validated pathways for retinal vascular diseases. The company intends to use new funding to expand operations and its R&D sector. As of this raise it remains clinical-stage and has secured $10M in Series A-3 funding. AsclepiX Therapeutics uses computational biology to identify potent peptide regulators of vascular homeostasis disrupted in retinal and oncologic diseases. Its lead investigational candidate, AXT107, emerged from the company’s computational discovery platform and targets VEGF-A, VEGF-C and activates Tie2, with preclinical data showing long durability and unique intravitreal gel depot delivery properties. AXT107 is being developed for diabetic macular edema (DME), wet age-related macular degeneration (wet AMD) and macular edema secondary to retinal vein occlusion (RVO), and the company expects to initiate clinical trials in the second half of 2020 with human studies poised to begin late 2020. AsclepiX says AXT107 could enable once-a-year intravitreal dosing, potentially reducing the treatment burden compared with current anti-VEGF therapies. The company is led by interim CEO Kevin Slawin and was co-founded by Aleksander S. Popel and Jordan J. Green of Johns Hopkins University School of Medicine. Financially, AsclepiX closed a $35 million Series A financing to fund Phase 1/2a clinical trials of AXT107. AsclepiX Therapeutics is a Baltimore-based biopharmaceutical company developing therapies from a novel peptide peptide platform. Its lead candidate, AXT107, targets multiple pathways including vascular endothelial growth factor A (VEGF-A) and Tie2 and is being developed to treat diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). In animal studies AXT107 was described as safe and superior to current approved therapies, potentially preventing and even reversing progressive retinal pathology with just two to three injections per year versus monthly injections for current drugs. The new funding will be used to complete an investigational new drug (IND) application for AXT107 and to plan phase 1/2 clinical studies first in subjects with DME and then in wet AMD. AsclepiX has expanded its board to add Josh Barer, Kevin Slawin, MD, and Sapna Srivastava, PhD alongside founding members Aleksander Popel, PhD and Jordan J. Green, PhD and CEO Wendy Perrow. The company has raised a total of $16 million to date, including $11 million in prior non-dilutive funding from the National Eye Institute, National Cancer Institute, TEDCO and others.